Ipca Laboratories Ltd

Ipca Labs. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Ipca Laboratories Ltd

₹ 726 1.65%
05 Jun 3:17 p.m.
ipca.com BSE: 524494 NSE : IPCALAB
About

Ipca Laboratories is engaged in the manufacturing and marketing of pharmaceuticals.(Source : 201903 Annual Report Page No: 68)

Key Points

Integrated nature of operations
Ipca Laboratories is a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. [1]
IPCA is among India’s top 20 pharmaceutical companies. [2]

Business segments FY22:
API Business (25%) [3]
Ipca produces over 80 APIs, nearly 79% of the APIs and Intermediates business is from exports making them one of India’s top exporters of APIs, serving over 100 countries around the globe. The core strategic focus has been on backward integration, resulting in superior supply chain reliability and cost competitiveness [4] [1] [5]

Website BSE NSE
  • Market Cap ₹ 18,418 Cr.
  • Current Price ₹ 726
  • High / Low ₹ 1,034 / 670
  • Stock P/E 39.1
  • Book Value ₹ 230
  • Dividend Yield 0.56 %
  • ROCE 11.6 %
  • ROE 8.32 %
  • Face Value ₹ 1.00
Edit ratios

Pros

Cons

  • Dividend payout has been low at 6.79% of profits over last 3 years

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
1,074 1,534 1,361 1,410 1,115 1,566 1,544 1,430 1,289 1,586 1,601 1,546 1,512
908 947 1,003 1,045 886 1,152 1,184 1,123 1,070 1,320 1,341 1,330 1,331
Operating Profit 166 587 358 365 229 414 360 308 219 266 260 216 181
OPM % 15% 38% 26% 26% 21% 26% 23% 22% 17% 17% 16% 14% 12%
14 12 15 15 20 21 18 12 15 22 36 31 36
Interest 4 3 2 2 2 2 1 1 3 7 9 11 18
Depreciation 64 51 52 54 52 56 57 59 61 62 64 67 70
Profit before tax 112 546 319 324 195 377 320 260 170 220 223 169 129
Tax % 26% 18% 16% 17% 16% 19% 21% 22% 17% 34% 35% 32% 37%
Net Profit 83 446 267 268 161 307 252 198 132 145 146 110 78
EPS in Rs 3.40 17.65 10.53 10.46 6.36 12.09 9.86 7.74 5.13 5.64 5.67 4.25 3.02
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
2,359 2,813 3,282 3,144 2,867 3,156 3,258 3,746 4,619 5,395 5,797 6,244
1,894 2,248 2,539 2,604 2,573 2,705 2,803 3,051 3,715 3,843 4,472 5,318
Operating Profit 465 565 743 541 294 451 455 695 904 1,552 1,325 927
OPM % 20% 20% 23% 17% 10% 14% 14% 19% 20% 29% 23% 15%
11 13 21 32 21 11 41 56 65 59 54 126
Interest 44 36 30 32 35 27 28 22 20 12 11 46
Depreciation 67 87 103 180 163 173 178 182 210 209 232 262
Profit before tax 364 454 631 361 117 262 291 546 739 1,389 1,136 745
Tax % 24% 29% 24% 28% 18% 26% 18% 19% 18% 17% 20% 34%
Net Profit 277 324 479 254 93 195 239 442 604 1,141 890 479
EPS in Rs 11.01 12.82 18.96 10.07 3.69 7.71 9.49 17.60 23.99 44.94 34.85 18.58
Dividend Payout % 15% 16% 13% 5% 0% 6% 5% 9% 10% 9% 11% 0%
Compounded Sales Growth
10 Years: 8%
5 Years: 14%
3 Years: 11%
TTM: 8%
Compounded Profit Growth
10 Years: 4%
5 Years: 15%
3 Years: -7%
TTM: -47%
Stock Price CAGR
10 Years: 9%
5 Years: 17%
3 Years: -2%
1 Year: -17%
Return on Equity
10 Years: 15%
5 Years: 17%
3 Years: 17%
Last Year: 8%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
25 25 25 25 25 25 25 25 25 25 25 25
Reserves 1,229 1,529 1,934 2,183 2,234 2,430 2,663 3,097 3,590 4,676 5,467 5,817
601 617 603 935 867 716 628 465 501 265 807 1,481
472 526 648 669 765 788 799 961 1,142 1,099 1,338 1,303
Total Liabilities 2,327 2,697 3,211 3,812 3,892 3,960 4,116 4,549 5,258 6,066 7,637 8,626
944 1,104 1,354 1,800 2,014 1,983 1,953 1,940 2,059 2,072 2,418 2,770
CWIP 95 129 165 267 129 95 73 66 133 235 306 122
Investments 34 9 9 16 26 136 87 120 310 505 989 626
1,255 1,455 1,683 1,729 1,723 1,746 2,003 2,422 2,756 3,254 3,924 5,109
Total Assets 2,327 2,697 3,211 3,812 3,892 3,960 4,116 4,549 5,258 6,066 7,637 8,626

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
354 389 522 468 709 282 341 501 570 1,090 856 806
-280 -260 -369 -689 -218 -149 -135 -165 -509 -521 -851 -725
-72 -83 -136 251 -462 -159 -130 -183 -137 -306 427 507
Net Cash Flow 2 46 18 29 29 -26 75 153 -76 264 432 588

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 54 54 50 41 57 58 67 66 71 55 57 58
Inventory Days 268 247 272 293 289 290 286 316 294 337 337 276
Days Payable 95 89 110 97 145 130 137 154 135 140 101 83
Cash Conversion Cycle 227 212 213 237 200 218 216 228 229 251 293 251
Working Capital Days 117 112 98 106 84 94 107 109 113 119 127 137
ROCE % 24% 24% 28% 14% 5% 9% 10% 16% 19% 31% 20% 12%

Shareholding Pattern

Numbers in percentages

Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
46.07 46.07 46.29 46.29 46.29 46.29 46.29 46.29 46.29 46.29 46.29 46.29
12.39 12.40 18.22 17.47 17.81 18.46 12.34 11.02 10.61 10.57 10.46 10.58
28.06 28.65 24.22 24.82 25.12 25.24 30.02 32.70 33.49 33.46 33.71 33.74
0.16 0.28 0.28 0.28 0.22 0.22 0.24 0.24 0.24 0.32 0.32 0.32
13.32 12.59 10.99 11.14 10.57 9.80 11.11 9.75 9.37 9.34 9.22 9.06

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls